Analyst picks & changes

Centocor Inc.


David Crossen of UBS Securities repeated a "buy." He said the positive reception at the American Heart Association meeting of


, CNTO's


inhibitor to block platelet aggregation, suggests the drug could become standard therapy in a high percentage of angioplasty and other procedures.

Read the full 498 word article

How to gain access

Continue reading with a
two-week free trial.